This study tests a new cancer treatment called **OriCAR-017** for people with relapsed or refractory multiple myeloma (RR/MM), a type of blood cancer. The study is in its early stages (Phase I/II) to check how safe the treatment is and how it works in the body. It's called an *open-label* study, meaning everyone knows what treatment is being given. The study involves different doses of the treatment given through an *IV infusion* (a drip). About 18 people will try three different dose levels, and more people will be added later. **Key Points:** - **Study Length:** Participation could last up to several months, with multiple visits required. - **Eligibility:** Adults aged 18-75 with specific health conditions can join. - **Risks & Benefits:** As a new treatment, there are risks; however, it might help some participants. People interested need to provide consent and meet specific health criteria. They can't join if they're pregnant, have certain infections, or have had specific treatments recently.